Fig. 4From: Integrative analysis of loss-of-function variants in clinical and genomic data reveals novel genes associated with cardiovascular traitsIn silico analysis of DGAT2 and in vivo effect of selective DGAT1 and DGAT2 inhibitors on bodyweight and glucose levels in male C57BL/6 mice. a Significant association within the BioMe Biobank cohort between non-carriers (n = 5469) and carriers (n = 8) of LoF DGAT2 mutation on glucose level (logistic regression, see Methods; p = 0.049, β = − 19, tβ = − 1.4). b Association between non-carriers (n = 4768) and carriers (n = 8) of LoF DGAT2 mutation on cholesterol levels (logistic regression, see Methods; p = 0.078, β = − 24, tβ = − 1.8). c Association between non-carriers (n = 4721) and carriers (n = 8) of LoF DGAT2 mutation on triglyceride levels (logistic regression, see Methods; p = 0.34, β = − 26, tβ = − 1.0). d Association from STARNET RNA-clinical trait analysis comparing DGAT2 expression levels with glucose levels in liver tissue (p = 0.024, β = 0.56). e Association from STARNET RNA-clinical trait analysis comparing DGAT2 expression levels with cholesterol levels in mammary artery (p = 0.036, β = 0.089). f Association from STARNET RNA-clinical trait analysis comparing DGAT2 expression levels with triglyceride levels in liver tissue (p = 0.0030, β = 0.27). g Body weight loss (ΔBW) of chow-fed mice treated for 3 days with vehicle, DGAT1 inhibitor (PF3), and DGAT2 inhibitor (PF9). h Short fasting blood glucose of chow-fed mice treated for 3 days with vehicle, DGAT1 inhibitor (PF3), and DGAT2 inhibitor (PF9) (n = 5). p < 0.05 (*), p < 0.01 (**), versus vehicle (student t-test)Back to article page